ProSciento Appoints Dr. Kelvin Logan, Former Executive at INC Research and Quintiles, to its Board of Directors

SAN DIEGO, May 30, 2017 /PRNewswire/ – ProSciento, a full scope clinical R&D services provider focused on diabetes, NASH and obesity, announced today the appointment of Dr. Kelvin Logan, former President of Europe, Asia and Latin America at INC Research, to its Board of Directors.

“Kelvin is a highly accomplished leader in the global clinical R&D industry, and we are very pleased to have an individual of his business and leadership acumen join our Board of Directors,” said Dr. Marcus Hompesch, ProSciento’s CEO and Chairman of the Board. “With his extensive experience and track record in driving strategic growth in the CRO industry, he will bring valuable insight to ProSciento’s Board as we continue our expansion into new geographies and additional capabilities.”

Dr. Logan is a life sciences executive with more than 30 years’ experience in the pharmaceutical and clinical research industry. He served as President of Europe, Asia and Latin America at INC Research, where he was instrumental in the expansion of INC Research’s global operations and partnerships throughout Central, Western and Eastern Europe, Asia, Japan, Australia, South Africa, and Latin America. Prior to joining INC Research, Dr. Logan was Senior Vice President and Senior Partner at Quintiles. In this role, he oversaw Quintiles’ clinical development services and operations in Europe for the CNS business unit and subsequently late phase clinical research. He also held leadership positions at Pharmaco LSR International, acquired by PPD in 1996.

“I’m extremely pleased to join ProSciento’s Board of Directors, a group consisting of highly respected leaders representing significant scientific and operational achievements in clinical R&D and within the pharmaceutical industry,” said Dr. Logan. “ProSciento is uniquely positioned for growth in today’s rapidly evolving clinical R&D industry as a therapeutically focused, specialty CRO providing full scope services and guidance based on robust scientific experience. I look forward to helping further shape the company’s strategic path forward.”

About ProSciento, Inc.

ProSciento is a metabolism-focused, full scope clinical R&D services provider, with a mission to advance the global development of novel therapeutics for diabetes, NASH and obesity. The company is widely recognized for quality and scientific excellence, an unparalleled methodological toolkit, and extensive experience with virtually all metabolic drug and device classes. Utilizing its scalable R&D services model – combining deep therapeutic area expertise, strategic planning, an unparalleled methodological tool kit, and operational execution from late preclinical to phase III readiness – ProSciento provides highly customizable services for its global client base in today’s rapidly evolving landscape of metabolic drug and device development. For more information, please visit

For media inquiries, please contact:
Abby Devine
Senior Director, Corporate Communications, ProSciento, Inc.
Tel: +1 858 663-6148

For business development inquires:

For clinical study enrollment inquires:
Tel: +1 (866) 308-7427

in cat NOT

Stay Connected

Would you like to receive updates from ProSciento?